Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme

Francesconi, Alessandra B., Dupre, Simon, Matos, Marco, Martin, David, Hughes, Brett G., Wyld, David K. and Lickliter, Jason D. (2010) Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. Journal of Clinical Neuroscience, 17 8: 970-974. doi:10.1016/j.jocn.2009.12.009


Author Francesconi, Alessandra B.
Dupre, Simon
Matos, Marco
Martin, David
Hughes, Brett G.
Wyld, David K.
Lickliter, Jason D.
Title Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme
Journal name Journal of Clinical Neuroscience   Check publisher's open access policy
ISSN 0967-5868
1532-2653
Publication date 2010-01-01
Year available 2010
Sub-type Article (original research)
DOI 10.1016/j.jocn.2009.12.009
Volume 17
Issue 8
Start page 970
End page 974
Total pages 5
Place of publication London, United Kingdom
Publisher Churchill Livingstone
Language eng
Abstract Relapsed glioblastoma multiforme (GBM) responds poorly to standard therapies. Vascular endothelial growth factor (VEGF) is implicated in the development of GBM and the anti-VEGF monoclonal antibody bevacizumab has shown early clinical promise against malignant glioma. We treated six patients with recurrent GBM using bevacizumab combined with carboplatin and etoposide chemotherapy (ACE regimen). Toxicity was that expected for carboplatin and etoposide alone, except for an ischemic stroke in one patient. We observed partial responses in five patients and one responding patient developed extensive tumour necrosis after 2 cycles of treatment. Median progression-free and overall survival was 19 and 29.9 weeks, respectively. Four responding patients developed recurrence, which was characterized by markedly less peri-tumoral edema, mass effect and necrosis compared with tumours at baseline. Two patients developed local extracranial extension. In conclusion, ACE was active in recurrent GBM and was mostly well tolerated.
Keyword Anti-angiogenic therapy
Bevacizumab
Carboplatin
Etoposide
Glioblastoma multiforme
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 31 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 34 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sat, 29 Aug 2015, 05:46:22 EST by System User on behalf of Medicine - Royal Brisbane and Women's Hospital